Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

InflaRx GmbH

www.inflarx.de

Latest From InflaRx GmbH

Pipeline Watch: Phase III Starts With NSR-REP1 Gene Therapy, ALLN-177 And BIVV009

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

IPOs In Review: Biopharma Offerings Bounced Back In 2017 As Returns Rose

With an average return of 33.2% in 2017, the number of biopharma IPOs that launched last year rose to 42 after falling to 30 in 2016 compared with 62 in 2015. Following a rough fourth quarter for biopharma stocks, will the IPO momentum continue in 2018?

Financing Business Strategies

Deals Shaping The Medical Industry, December 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance or Financing. This month’s column covers deals announced in November 2017.

Deals BioPharmaceutical

IPO Update: Biopharma Firms Give Thanks For Receptive US Investors

Six biopharma firms went public in the US in November during the three weeks leading up to Thanksgiving, raising $539.5m and counting. With 39 IPOs so far this year, 2017 has had nine more first-time offerings than 2016 with five more weeks to go.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • In Vitro Diagnostics
  • Pharmaceuticals
  • Therapeutic Areas
  • Immune Disorders
  • Infectious & Viral Diseases
  • Inflammation
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Germany
  • Parent & Subsidiaries
  • InflaRx GmbH
  • Senior Management
  • Niels Riedemann, PhD, CEO
    Arnd Christ, CFO
    Renfeng Guo, MD, CSO
    Othmar Zenker, MD, CMO
    Maria Habel, PhD, Head of Pre-Clinical R&D
  • Contact Info
  • InflaRx GmbH
    Phone: (49) 3641 508 180
    Winzerlaer Str. 2
    Jena, D-07745
    Germany
Advertisement
Advertisement
UsernamePublicRestriction

Register